Sangamo Therapeutics, Inc. (LON: 0R1D)
London
· Delayed Price · Currency is GBP · Price in USD
1.200
-0.020 (-1.64%)
Jan 31, 2025, 7:03 PM BST
Sangamo Therapeutics Employees
Sangamo Therapeutics had 405 employees as of December 31, 2023. The number of employees decreased by 73 or -15.27% compared to the previous year.
Employees
405
Change (1Y)
-73
Growth (1Y)
-15.27%
Revenue / Employee
96.33K GBP
Profits / Employee
-248.41K GBP
Market Cap
206.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Sangamo Therapeutics News
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO - Accesswire
- 3 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO - Accesswire
- 15 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO - Accesswire
- 16 days ago - Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO) - Accesswire
- 18 days ago - Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO) - Accesswire
- 18 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - Accesswire
- 18 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - Accesswire
- 19 days ago - Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SGMO - Accesswire